Nautilus Biotechnology, Inc. (NAUT) stock forecast and price target
Price $2.32 · data as of November 13, 2026
12-month price target
Average target$4.00
Upside / downside+72.4%
Analysts3
ConsensusNone
Analyst ratings
Strong buy 0Buy 4Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.48 | — | $668500 |
| Next fiscal year ends December 31, 2027 | $-0.48 | — | $6M |
| Next quarter ends December 31, 2026 | $-0.13 | — | $262500 |
| Quarter after ends March 31, 2027 | $-0.12 | — | $387500 |
Consensus of the analysts covering Nautilus Biotechnology, updated daily. In the last 30 days 3 estimates were raised and 0 lowered.
Frequently asked questions
What is the Nautilus Biotechnology stock price target?
The average 12-month target from 3 analysts is $4.00, 72.4% above the current price of $2.32 Targets range from $4.00 to $4.00.
Is Nautilus Biotechnology a buy according to analysts?
The consensus rating is “None” (4 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Nautilus Biotechnology expected to earn?
Analysts expect EPS of $-0.48 for the fiscal year ending December 31, 2026 and $-0.48 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.